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Abstract: Crohn’s disease is an incurable and frequently progressive entity with major impact on
affected patients. Up to half of patients require surgery in the first 10 years after diagnosis and over
75% of operated patients require at least one further surgery within lifetime. In order to minimize
surgical risk, modifiable risk factors such as nutritional status need to be optimized. This systematic
review on preoperative nutritional support in adult Crohn’s patients between 1997 and 2017 aimed
to provide an overview on target populations, screening modalities, routes of administration,
and expected benefits. Pertinent study characteristics (prospective vs. retrospective, sample size,
control group, limitations) were defined a priori. Twenty-nine studies were retained, of which 14
original studies (9 retrospective, 4 prospective, and 1 randomized controlled trial) and 15 reviews.
Study heterogeneity was high regarding nutritional regimens and outcome, and meta-analysis
could not be performed. Most studies were conducted without matched control group and thus
provide modest level of evidence. Consistently, malnutrition was found to be a major risk factor
for postoperative complications, and both enteral and parenteral routes were efficient in decreasing
postoperative morbidity. Current guidelines for nutrition in general surgery apply also to Crohn’s
patients. The route of administration should be chosen according to disease presentation and patients’
condition. Further studies are needed to strengthen the evidence.
Keywords: Crohn’s; inflammatory bowel disease; nutrition; supplement; surgery; preoperative;
complications
1. Introduction
Nutritional support strategies in malnourished patients became widely accepted tool to decrease
postoperative morbidity in major gastrointestinal surgery [1,2]. Up to 85% of patients with Crohn’s
disease awaiting surgery are malnourished as a consequence of active and disabling disease [3],
impeding proper dietary intake and resorption [4–6]. Since up to 70% of Crohn’s patients at some
point requires surgery [7,8], a bowel-sparing attitude is mandatory in order to prevent short bowel
syndromes, malnutrition, and anemia [9,10]. Despite advances in non-surgical management of
acute flares through multimodal concepts including biologics, antibiotics, and nutritional support,
surgery remains a last treatment option for medically exhausted cases [11–13]. Interestingly,
it should be emphasized that incidence of surgical procedures for Crohn’s disease did not decrease
after introduction of infliximab [14]. Postoperative complication rates, including most feared
intra-abdominal septic complications, reach 30% [15,16]. Nutritional guidelines for Crohn’s patients
have been published by the European Society for Clinical nutrition and metabolism (ESPEN) in
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2006 [17] and 2016 [4]. Most recommendations are based on consensus among experts or extrapolated
from the general surgical population.
The aim of this present study was to systematically review scientific evidence over the last 20 years
in an attempt to provide evidence-based recommendations.
2. Materials and Methods
2.1. Data sources and Search Strategies
Main electronic databases including Medline (searched through PubMed), Embase, the Cochrane
Database of Systematic Review and the Cochrane Central Register of Controlled trials were
systematically searched. For searching PubMed, the medical subject heading (MeSH) were “(Crohn OR
Crohn’s Disease OR inflammatory bowel disease) AND (nutrition OR conditioning OR nutritional
support) AND (preoperative OR perioperative)”.
Electronic links were searched for related articles and cross-referencing of selected articles was
performed by two authors (FG, BP). The trial registry http://clinicaltrials.gov was screened for relevant
unpublished prospective trials. The search was limited to studies published between 1 January 1997
and 28 February 2017 for the following reasons: First, to provide evidence over the last 20 years,
considering 10 years before the implementation of guidelines [17] and 10 years thereafter. Second,
U.S. Food and Drug Administration approval of infliximab was granted in 1997 [14]. All kinds
of original scientific reports were considered, and reviews and book chapters were also included.
No language restrictions were applied for the original search, but studies providing only English
abstracts were consequently excluded.
2.2. Study Selection (Inclusion and Exclusion Criteria)
Original studies and reviews reporting on pre- or perioperative nutritional support in Crohn’s
disease were included. Excluded from the analysis were reports on general nutritional support in
Crohn’s disease (including postoperatively) or in pediatric populations. The included manuscripts
were divided in original scientific reports and reviews.
2.3. Data Extraction and Quality Assessment
Pertinent study characteristics (prospective vs. retrospective, sample size, control group,
matching) were defined a priori and each manuscript was assessed for potential sources of bias.
Two authors independently performed the literature search. The search terms were firstly identified in
the title, and secondly in the abstract or medical subject heading. All studies of interest were obtained
as full text articles and scrutinized thoroughly. Three authors made the final decision on inclusion of
a study.
Relevant data were extracted and documented in a database developed ad hoc for all
publications. The following items were recorded for each study when available: authors,
title, year of publication, disease presentation/surgical indication, details on nutritional regimen
(type/formula/duration/timing), and potential limitations of original studies. Postoperative outcomes
of interest were complications (overall, infectious/septic, non-infectious), recurrence rates, and changes
in different nutritional parameters if available. Data are presented in accordance to the PRISMA
statement [18] (Figure 1).
Based on the findings of this study, an algorithm was created for practical guidance.
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Figure 1. The selection process adhere to the guidelines outlined in the PRISMA statement [18]. 
Based on the findings of this study, an algorithm was created for practical guidance. 
2.4. Data Analysis 
Meta‐analysis of results was not feasible due to limited and heterogeneous original data. Instead, 
tables were created with descriptive statistics to display the most relevant findings of each original 
study and review to give a comprehensive overview of the most relevant results.   
3. Results 
Electronic search of PubMed yielded 189 studies. By cross‐referencing and through other data 
sources,  two  further  studies  [16,19] were  identified matching  the  inclusion  criteria. Of  these  191 
studies,  121 were  excluded based on  the  title,  and  35  further  studies based on  the  abstract with 
reasons  for  exclusion  displayed  in  Figure  1,  remaining  35  full  text  articles  assessed.  Six  were 
subsequently excluded  for  the  following  reasons:  incomplete data or not within  the  scope of  the 
present analysis (n = 4) [20–23], language restriction (n = 1) [24], and risk of double publication (n = 1) 
[25] (Figure 1). For final analysis, 14 original studies [26–39] and 15 reviews [4,5,17,19,40–50] were 
retained (Tables 1–3). All studies except one were indexed in PubMed. The one not indexed was a 
conference paper  [51]  from Cochrane Database with no detailed data  thus was excluded  for  final 
analysis. Two studies were found on http://clinicaltrials.gov, one completed study from a Chinese 
Figure 1. The selection process adhere to the guidelines outlined in the PRISMA statement [18].
2.4. Data Analysis
Meta-analysis of results was not feasible due to limited and heterogeneous original data. Instead,
tables were created with descriptive statistics to display the most relevant findings of each original
study and review to give a comprehensive overview of the most r l vant r s lts.
3. Results
Electronic search of PubMed yielded 189 studies. By cross-referencing and through other data
sources, two further studies [16,19] were identified matching the inclusion criteria. Of these 191
studies, 121 were excluded based on the title, and 35 further studies based on the abstract with reasons
for exclusion displayed in Figure 1, remaining 35 full text articles assessed. Six were subsequently
excluded for the following reasons: incomplete data or not within the scope of the present analysis
(n = 4) [20–23], language restriction (n = 1) [24], and risk of double publication (n = 1) [25] (Figure 1).
For final analysis, 14 original studies [26–39] and 15 reviews [4,5,17,19,40–50] were retained (Tables 1–3).
All studies except one were indexed in PubMed. The one not indexed was a conference paper [51]
from Cochrane Database with no detailed data thus was excluded for final analysis. Two studies ere
found on http://clinicaltrials.gov, one completed study from a Chinese group (NCT01540942) and
one Canadian study which was not yet recruiting by 8 March 2017 (NCT02985489).
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3.1. Methodological Assessment of Inlcuded Studies
3.1.1. Study Design and Quality of Original Studies
Overall, 2141 patients with Crohn’s disease were reported in study and control groups,
respectively (Table 1). Nine studies (64%) were retrospective [26,27,29,30,32–34,36,37] totaling
1783 patients. The remaining 358 patients were studied in 4 (29%) prospective [28,35,38,39] and
1 randomized controlled trial (RCT) [31]. In the only RCT, patients were not randomized to a
nutritional regimen but to different endpoint measures, and thus no nutritional control group was
available. Nutritional control groups were available in nine studies (64%) [26,28–30,32,33,35,37,38].
Only three studies (21%) [26,29,35] matched study and control groups, however, matching criteria
were inconsistent among these studies.
Table 1. Original studies on preoperative nutritional support in Crohn’s disease patients.
Author Year Design Control Matching N Limitations
Heerasing [26] 2017 Retrospective Yes Yes 114 Incomplete matching for disease severity
Guo [27] 2017 Retrospective No na 118 No outcome data other than SSI
Beaupel [28] 2017 Prospective Yes No 56 Comparison high-risk to low-risk patients
Wang [29] 2016 Retrospective Yes Yes 81 Potential selection bias for study group
Zhang [30] 2015 Retrospective Yes No 64 Comparison high-risk to low-risk patients
Zhu [31] 2015 RCT No na 108 No nutritional control group
Li [32] 2015 Retrospective Yes No 708 Potential selection bias, <10% laparoscopy
Li [33] 2014 Retrospective Yes No 123 No dietary information of control group
Bellolio [34] 2013 Retrospective No No 434 No nutritional control group
Jacobson [35] 2012 Prospective Yes Yes 120 No matching for disease severity
Zerbib [36] 2010 Retrospective No Na 78 Heterogeneous study groups
Grivceva [37] 2008 Retrospective Yes No 63 Composition of diets not specified
Yao [38] 2005 Prospective Yes No 32 Small sample size
Smedh [39] 2002 Prospective No na 42 Small sample size, no nutritional control group
Abbreviations: RCT—randomized controlled trial, SSI—surgical site infection, N—number of included patients,
na—not available
3.1.2. Patients, Disease Presentation and Nutritional Details
In 12 studies (86%) nutritional support was administered preoperative only, ranging from two
weeks up to three months. The remaining two studies [31,38] administered nutritional support
pre- and postoperatively. Nutritional regimens were heterogeneous among included studies.
Details on formulas are displayed in Table 2. In six studies (43%) [30,31,34,36,37,39], nutritional
formulas were not or incompletely described. Six studies [26,28,29,32,33,39] evaluated the impact
of exclusive enteral nutrition (EEN), four studies [34,35,37,38] reported on total parenteral nutrition
(TPN) and four studies [27,30,31,36] combined different ways of nutritional support. Most studies
(71%) [26,28,30–35,37,38] reported on severely sick and malnourished patients with either obstructing
or fistulizing disease (Table 2). The remaining studies [27,29,36,39] optimized their cohorts or reported
on low-risk patients.
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Table 2. Nutritional details and outcome of original studies.
Author Disease Type/Formula Timing Duration Groups/Cohort Main results (Nutritional Group)
Heerasing [26] P/F EEN 1 Pre 6 w (mean)
EEN pre-treatment group vs. straight to
surgery group
Nine-fold decreased infectious complications, shorter
operating time
Guo [27] F PN+EN 2 Pre 3 m
Preop optimized cohort (nutritional support, steroid
weaning, abscess drainage, antibiotics) EEN <3 m retained as independent risk factor for SSI
Beaupel [28] P/F ANS-TGF-b2(EEN) Pre 3 w (median)
Supplemented high-risk (steroids, malnutrition) vs.
non supplemented low-risk patients Similar overall and infectious complications
Wang [29] FS EEN 2 Pre 4 w
Low-risk patients (no immunosuppression, no
inflammation) in both groups (EEN vs. non-EEN)
Decreased overall and infectious complications,
less recurrence at 6 m
Zhang [30] F/O TPN or PN orEN (na) Pre 3 w (median)
Fortified nutrition support group (lower BMI, higher
CDAI) vs. non-supplemented control group Similar postoperative septic complications (3 m)
Zhu [31] F/P EEN
2 +/-PN
+/-TPN (na)
Pre Post 4 w 4 w Supplementation in all patients, randomization andblinding for two endpoints: ROI and IOM
Similar complications (4 w) in ROI group = better
endpoint than IOM, less complications than historical
controls
Li [32] R/F/O/P EEN 2 Pre 4 w
Immunosuppressants-treated EEN patients vs.
different non-supplemented control groups
Decreased overall and infectious complications
(30 days) in EEN-group
Li [33] F EEN 3 Pre 3 m
EEN group vs. normal diet group, abscess-drainage
in all patients
Decrease of intra-abdominal septic complications
at 3 m
Bellolio [34] P/N-P TPN (na) Pre na TPN for bowel rest in patients with penetratingdisease vs. few TPN in non-penetrating disease
Similar complication rates in both groups, beneficial
effect of TPN and bowel rest
Jacobson [35] O TPN [52] Pre 46 days (mean) Matched cohort of preoperative TPN vs. straight tosurgery group
Clinical remission achieved, postoperative
complications (30 days), decreased
Zerbib [36] F/P EN 4/TPN (na) Pre 2 w/3 w
Preop optimized cohort (nutritional support, steroid
weaning, abscess drainage, antibiotics)
Low postoperative morbidity (30 days) and stoma
rate within a standardized pathway
Grivceva [37] FS TPN (na) Pre 12 days (mean) PN group (with lower BMI and higher CDAI) vs.non-supplemented control group
Improvement of BMI/CDAI, no difference
in outcome
Yao [38] O TPN 5 Peri 3 w
Severely malnourished cohort (BMI <15), TPN group
vs. non-supplemented control group
TPN ameliorates immunity, reverses malnutrition
(BMI), facilitates recovery
Smedh [39] F/FS EEN (na) Pre 3–6 w Preoperative optimized cohort (EEN in 50% ofpatients, steroid weaning, abscess drainage)
Few postop complications (30 days) compared to
historical control groups
1 Modulen IBD (Nestle, Vevey, Switzerland), 2 Peptisorb Liquid, Enteral Nutrition Suspension; Nutricia Company, Amsterdam, the Netherlands, 3 Peptison Liquid, Nutricia Company,
(Shanghai, China), 4 elemental diet >30 kcal/kg ideal body weight/day, 5 nitrogen 0.2 g/kg/day, 30 kcal/kg/day, fat 40%; glucose 60%. Abbreviations: P—Penetrating, F—Fistulizing,
FS—Fibrous Stenosis, O—Obstructing, R—Refractory Disease, EEN—Exclusive Enteral Nutrition, PN—Parenteral Nutrition, EN—Enteral Nutrition, TPN —Total Parenteral Nutrition,
na—not available, w—weeks, m—months, d—days, Preop—Preoperative, Postop—Postoperative, BMI—Body Mass Index, CDAI—Crohn’s Disease Activity Index, ROI—reduction of
inflammation, IOM—improvement of malnutrition.
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3.2. Outcome
Five studies [26,29,32,33,35] showed significantly better results in terms of overall and infectious
complications in groups undergoing preoperative nutritional therapy compared to control groups
(Table 2). Among these studies, four [26,29,32,33] used EEN formulas and one [35] TPN. In the study
of Heerasing et al. [26], 25% of patients could avoid surgery due to EEN induced remission and were
bridged to alternative immunosuppressant therapy, but follow-up was limited to one year. Further
effects of EEN were a significant decrease in CRP levels, surgical complications (8% vs. 32%) and
infectious complications (abscess, collection, or leak, 3% vs. 20%) [4]. Wang et al. [29] showed an
effect of EEN on different nutritional parameters (significant improvement of BMI, anemia and CRP
levels), significantly lower infectious (21% vs. 44%) and non-infectious (26% vs. 51%) complication
rates and less recurrence at six months (7% vs. 26%). Lower incidences of total (19% vs. 29%) and
specific infectious complications (wound infection, abscess, and leak) were observed in the study of
Li et al. [32] when comparing the steroid-weaned EEN group with the steroid-weaned control group.
Further, supplemented patients needed less emergency surgeries compared to the different control
groups. Li et al. [33] demonstrated a significant improvement of albumin and CRP levels after EEN
therapy and at three months postoperatively, intra-abdominal septic complications were significantly
lower (4% vs. 18%). In the cohort of Jacobson [35], patients pre-treated with TPN showed clinical
remission and improved nutritional status (albumin, weight) at the time of surgery and no serious
early (30 days) postoperative complications were observed in these 15 consecutive patients, contrarily
to 28% in the matched control group.
Three studies [28,30,37] could not demonstrate differences in outcome due to unequal
nutritional baseline conditions between nutritional and control groups, as detailed in Table 2.
Three studies [31,36,39] without control groups compared their results to historical controls of other
authors and found overall complication rates of 14% [39] and 18% [31]. However, these two studies
were designed to compare nutritional endpoints [31] and anastomotic techniques [39] rather than
focusing on impact of nutritional support. The preoperatively optimized cohort of Zerbib et al. [36]
with 64% of patients receiving nutritional support (in combination with bowel rest, weaning of
steroids, abscess drainage, and antibiotics) presented an overall morbidity of 18% and a low rate
of fecal diversion. Another study without a control group by Guo et al. [27] identified EEN of
<3 months, preoperative anemia and bacteria in fistula tract as independent risk factors for surgical site
infection (31%), while preoperative abscess drainage represented a protective factor. Another study
did not compare nutritional regimens [34], but reported TPN in combination with antibiotics, drainage,
and postponed surgery in patients with penetrating disease which led to similar complication rates
compared to patients with non-perforating disease (13% vs. 11%). The cohort of Yao et al. [38] was
severely malnourished and half of patients were supplement by TPN one week before surgery and
continued two weeks postoperatively. IgM levels decreased and BMI increased significantly in the
study group, while no changes were observed in the control group. No difference was found regarding
overall postoperative complications between the two groups (27% each), but a six month follow-up
showed that the rate of resuming work was higher in the study group [38].
3.3. Reviews
Fifteen reviews, guidelines or book chapters were retained [4,5,17,19,40–50] (Table 3). Most of
them (80%) [5,19,40–44,46–50] were narrative, and only two (13%) [4,17] did perform systematic search
to provide official guidelines by the ESPEN society. The more recent recommendations advocate:
- enteral nutrition always preferred over parenteral nutrition in malnourished patients (weight
loss >10–15% within six months, BMI <18.5 kg/m2, albumin <30 g/L)
- postpone surgery for 7–14 days if possible
- parenteral nutrition should be used as supplementary to enteral nutrition if >60% energy needs
cannot be met via the enteral route
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These recommendations are congruent and 1:1 extrapolated from guidelines on enteral
nutrition [53,54].
All reviews are consistent among each other regarding conclusions and agree on the importance
of perioperative nutritional support. Further, they provide recommendations in line with current
guidelines: if compared, enteral nutrition should be the preferred route of administration. All reviews
underline the importance of a multimodal approach (preoperative optimization). Evidence-based
recommendations however are scarce, since no solid evidence is available, and all authors agree that
more high quality studies are needed to establish solid recommendations. Further, the impact of
specific components of nutritional supplements should be studied to provide further evidence-based
formulas [5,41].
Table 3. Reviews on preoperative nutritional support in Crohn’s disease patients.
Author Year Design Aim/Conclusions
Forbes [4] 2016 Guidelines 64 recommendations to guide nutritional support in IBD patients.
Nguyen [5] 2016 N. Review Preoperative optimization by enteral and parenteral nutritionmandatory. Timing, route of administration, type, duration debated.
Nickerson [40] 2016 N. Review Perioperative optimization imperative for favorablepostoperative outcome.
Schwartz [41] 2016 N. Review Evidence in favour of PN, but larger trials needed.
Montgomery [42] 2015 N. Review Recommendations for nutritional assessment andpreoperative optimization.
Horisberger [43] 2015 Book chapter Preoperative protein supplements (at least one week) beneficial.
Crowell [44] 2015 N. Review Preoperative optimization (nutritional support, abscess drainage)prevent septic complications and early recurrence.
Spinelli [45] 2014 N. Review Preoperative optimization crucial for surgical outcome, preoperativeenteral nutrition for at least 10–14 days to prefer over TPN.
Triantafillidis [19] 2014 N. Review Indications for TPN are the same as in every major surgical patient.
Sharma [46] 2013 N. Review Enteral support (immunonutrition and elemental diet)preferred over TPN.
Iesalnieks [47] 2012 N. Review Preoperative enteral nutrition might be beneficial,more evidence needed.
Wagner [48] 2011 N. Review EN preferred, preoperative and postoperative PN remain alternatives.Consider immunonutrition, fish oils, and probiotics.
Efron [49] 2007 N. Review Perioperative TPN might be beneficial, more high qualitystudies needed.
Lochs [17] 2006 Guidelines No specifics for Crohn’s patients, perioperative nutrition as ingeneral GI surgery.
Husain [50] 1998 N. Review Nutrition has a critical benefit in postoperative Crohn’s disease.
Abbreviations: N—Narrative, Postop—postoperative, PN—Parenteral Nutrition, TPN—Total Parenteral Nutrition,
EN—Enteral Nutrition, IBD—Inflammatory Bowel Disease, GI—gastrointestinal.
4. Discussion
This systematic review scrutinized available evidence over the last 20 years to provide
evidence-based guidelines for perioperative nutritional support in patients suffering from Crohn’s
disease. Fourteen original studies evaluated nutritional support in mostly severely ill patients,
and a large heterogeneity was observed among studies regarding type, formula, and timing of
nutrition. Only few prospective studies were available, and a randomized controlled study comparing
different nutritional strategies was not to date. Hence, comparison between studies is delicate,
and conclusions should be drawn cautiously. Even though nutritional support strategies were different,
all studies presented encouraging results and emphasized the importance of nutritional support
within a multimodal preoperative optimization concept. Some general principles in patients suffering
from Crohn’s disease must be discussed, including particularities of Crohn’s patients, screening
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modalities, and current guidelines, which are discussed and compared to the evidence provided by
this systematic review.
4.1. Particularities in Surgery for Crohn’s Disease
Patients suffering from Crohn’s disease are a particular subset of patients in many ways. At the
time of surgery, most patients are treated by immunomodulating drugs, present with intra-abdominal
infections, and are anemic and malnourished [55]. In a recent meta-analysis, steroid use, low
albumin level, preoperative surgical history, and preoperative abscess were retained as risk factors
for adverse surgical outcome [56]. Besides steroids and thiopurines, biologics such as anti-TNF
provide new treatment options for disease control [57]. However, the influence of these drugs on
postoperative outcome is matter of debate. While Fumery et al. described an increased risk of
complications [15], a recent meta-analysis did not find any association between immunomodulating
therapy and postoperative outcome [58]. Malnutrition on the other hand is common (up to 85%) among
Crohn’s patients awaiting surgery and is a well-known risk factor for adverse postoperative outcome
in surgical patients in general [59]. For Crohn’s patients needing surgery, anastomotic dehiscence,
intraabdominal abscess, and fistula, regrouped as intraabdominal septic complications, represent
most feared complications [60,61]. Intraabdominal septic complications hinder the postoperative
course in up to 20% of patients with potentially severe consequences [15,62] and either reoperation
or percutaneous drainage is needed in most cases. Hence, efforts to improve modifiable risk factors
before surgery are of utmost importance.
4.2. Guidelines for Perioperative Nutrition and Preoperative Optimization
By the time of official ESPEN guidelines publication in 2006 [17], specific data on the effect
of perioperative nutrition was lacking. Considerable evidence on nutritional support in general
gastrointestinal surgery and in critically ill patients led by extrapolation to the recommendation to treat
Crohn’s patients accordingly [17]. This message was reinforced 10 years later by revised guidelines [4].
Hence, the ESPEN guidelines on enteral nutrition for surgery [53], published in 2006 and 2017 [54], do
apply for Crohn’s patients if they tolerate nutritional supplements to meet their metabolic needs. Most
recommendations concerning enteral nutrition were elaborated on firm evidence and are hence highly
recommended [53,54]. Whenever possible, the route of administration should be enteral, which is also
advocated for patients with Crohn’s disease [17]. This was previously emphasized by a review on
nutritional support strategies in Crohn’s disease [63]. Guidelines for parenteral nutrition [64] in the
perioperative phase do likewise apply for Crohn’s patients if metabolic needs are not met by enteral
nutrition alone or if disease presentation at the time of scheduled surgery impedes enteral nutrition
(e.g., intestinal obstruction or high output fistula). Nutritional guidelines merge with enhanced
recovery after surgery (ERAS) guidelines [65], which are beneficial for surgical patients regarding
outcome, length of stay, and costs. Recent reports suggested that enhanced recovery combined with
minimally invasive techniques may lead to further improvements in surgical outcomes of Crohn’s
patients [66,67]. Whenever possible, elective surgical patients should be treated according to the
ERAS protocol: avoidance of long term fasting, integration of nutritional strategies into the overall
management of the patient, metabolic homeostasis, and early mobilization [4].
Nutritional strategies need to be part of a concept called preoperative optimization, including
weaning of steroids if possible, drainage of percutaneous abscesses if applicable, and intravenous
antibiotics if indicated [68]. Several of the studies retained for the present analysis presented promising
data within such a multimodal approach [27,36,39,40,42]. Thus, surgery has to be delayed if possible
in order to ensure best conditions. In case of emergency, EN or PN should start postoperatively [4].
4.3. Nutritional Screening
Several original studies [30,37,38] retained for the present analysis reported on nutritional
screening tools or markers to provide nutritional support, especially by emphasizing the importance
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of body mass index (BMI). They all identified BMI as a follow-up tool of nutritional status during
parenteral nutritional therapy. Recent guidelines advocate BMI <18.5 kg/m2, weight loss >10–15%
within six months and serum albumin <30 g/L as best reflectors of severe undernutrition in
Crohn’s disease [4]. Concerning screening, ESPEN guidelines for Inflammatory Bowel Disease [4]
recommend that Crohn’s patients should be screened for malnutrition as patients undergoing general
surgery [53,54] through validated screening tools. Particularly recommended are the Nutritional Risk
Score (NRS) [69] and the Malnutrition Universal Screening Tool (MUST) [70]. Patients with a NRS ≥3
are considered to be at risk for gastrointestinal surgery [71].
4.4. Further Nutritional Strategies for Perioperative Support in Crohn’s Patients
Two concepts need special consideration as result of this systematic review: EEN and TPN.
Interestingly, most included studies reported on either EEN or TPN or a combination of both.
EEN, either in elemental or polymeric form, has a direct anti-inflammatory effect [72], promotes
mucosal healing [73], modifies intestinal microflora [74], and might decrease the antigenic load
through bowel rest. EEN can induce clinical remission in pediatric and adult patients [75,76], as
observed by Heerasing et al. [26] in 25% of patients awaiting surgery. In a recent review analyzing
EEN in non-surgical Crohn’s patients [77], EEN has been associated with remission rates of up to 80%.
Wang et al. [29] observed decreased recurrence rates at six months in the EEN group, however, clinical
recurrence was similar two years after surgery in both groups. Li et al. [32] and Smedh et al. [39]
further presented interesting data on EEN allowing subsequent steroid-weaning, contributing to lower
complication rates in EEN-groups in these studies. Disease presentations were severe in all studies
with EEN [26,28,32,33,39] but one, [29], and might thus be particularly useful in this context (Table 2).
TPN was mainly used for penetrating disease in the study of Bellolio et al. [34], and Yao et al. [38]
and Jacobson [35] treated patients with obstructing disease to observe improved immunity and clinical
remission. Concerning formulas and timing, data was heterogeneous. Hence, no solid conclusions
can be drawn. As a consequence, guidelines on parenteral nutrition [64] should be used for guidance.
Schwartz [41] emphasized the need for larger prospective trials to strengthen the evidence. With this
respect and due to lacking data, parenteral nutrition should be reserved for patients who are unable to
cover their energetic needs by enteral nutrition.
Further considerations regarding routes of administration and associated potential complications
have been published before [63].
4.5. Particularities in Perioperative Nutrition for Crohn’s Disease
Despite the particularities of Crohn’s disease and potential clinical discrepancies with the general
surgical population including disease flares at time of surgery, exhaustive immunomodulating and
medical treatment, and unfavorable baseline conditions, guidelines on enteral and parenteral nutrition
including screening modalities, nutritional support strategies, and nutritional follow-up can be
extrapolated to Crohn’s patients. However, severe malnutrition in high-risk patients or inability
to cover energy needs in patients with obstructing or fistulizing disease might impede conventional
nutritional support (including oral nutritional supplements and immunonutrition) [4]. In these
circumstances, specific nutritional support strategies including EEN or TPN have to be discussed.
The following algorithm gives an overview on treatment suggestions considering available guidelines
and the evidence of this systematic review (Figure 2).
Several limitations of the present study need to be mentioned. Due to heterogeneity of data and
modest study quality of original studies regarding nutritional treatment strategies, solid conclusions
cannot be drawn, and further high-quality evidence will be needed. The suggested treatment algorithm
(Figure 2) should thus rather help in decision-making than provide formal recommendations.
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